The Relationship Between the Level Fabp4, Risks of Type 2 Diabetes Mellitus, and Cardiovascular Events

Yelena Laryushina; Viktoriya Parakhina; Anar  Turmukhambetova; Lyudmila  Turgunova; Lyazat  Ibraeva; Dana  Amirkhanova; Farida  Nildibayeva

doi:10.3889/oamjms.2020.4678

Authors

Yelena Laryushina Department of the Internal Medicine No. 2, Karaganda Medical University, Karaganda, Kazakhstan
Viktoriya Parakhina Department of Medicine, Karaganda Medical University, Karaganda, Kazakhstan
Anar Turmukhambetova Department of Strategic Development and Science, Karaganda Medical University, Karaganda, Kazakhstan
Lyudmila Turgunova Department of the Internal Medicine No. 2, Karaganda Medical University, Karaganda, Kazakhstan
Lyazat Ibraeva Department of the Internal Medicine No. 3, Karaganda Medical University, Karaganda, Kazakhstan
Dana Amirkhanova Department of the Internal Medicine No. 2, Karaganda Medical University, Karaganda, Kazakhstan
Farida Nildibayeva Department of the Internal Medicine No. 2, Karaganda Medical University, Karaganda, Kazakhstan

DOI:

https://doi.org/10.3889/oamjms.2020.4678

Keywords:

FABP4, SCORE, FINDRISC, endothelial dysfunction

Abstract

BACKGROUND: The normoglycemic patients with diabetes risk and prediabetes have insulin resistance and consequently endothelial dysfunction that possible causes macroangiopathy and adverse cardiovascular events and further mortality of it. An early diabetes risk identification using not only prognostic scales but also biomarkers is starting and crucial point of struggle with 2 type diabetes mellitus and its complications.

AIM: The aim of the study is to estimate the impact of FABP4 biomarker on diabetes risk and cardiovascular events.

METHODS: A cross-sectional study was conducted simultaneously among 389 respondents aged 18–65 years. We provided survey and clinical examinations. The risk of diabetes was assessed using the FINDRISC scale and cardiovascular risk (CVR) was assessed using SCORE scale.

The serum FABP4 biomarker was studied using a multiplex assay, immunofluorescence using XMap technology, a Bioplex 3D instrument, and a MILLIPLEX^®Human cardiovascular disease panel I reagent kit(Millipore). Results were considered statistically significant at p < 0.001.

RESULTS: The group of type 2 diabetes mellitus (T2DM) high risk was 79 (20%) of all study participants. The level of the FABP4 marker significantly prevailed in high-risk group of T2DM and high CVR was also established this group. We found a positive direct average correlation(r = 0.59; p = 0.000) between FABP4 and FINDRISC scale. The logistic regression analysis indicated that the level of the FABP4 marker increases withing the increased risk of T2DM. The correlation between FABP4 concentration and CVR according to the SCORE scale (r = 0.24; p = 0,000) was lower than between FABP4 and diabetes risk. Risk factors were established affecting on the increasing CVR by SCORE scale in patients with T2DM risk.

CONCLUSIONS: The level of FABP4 significantly prevailed in the group of diabetes and cardiovascular risk (CVR). The established correlations between FABP4 level and CVR or T2DM risk indicate on its increase in groups with a higher risk of type 2 diabetes and a high CVR.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017. Available from: http://www.diabetesatlas.org. [Last accessed on 2019 Jan 23].

The National Register of the Republic of Kazakhstan; 2018. Available from: http://www.rcrz.kz/files/sbornik/sbornik_2018- converted.pdf. [Last accessed on 2020 Mar 20].

Kannel W, McGee D. Diabetes and cardiovascular risk factors: The Framingham study. Circulation. 1979;59(1):8-13. https:// doi.org/10.1161/01.cir.59.1.8 PMid:758126

Yang Z, Shen Y, Shen W, Pu L, Meng H, Zhang R, et al. Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with T2DM and stable coronary artery disease. J Am Coll Cardiol. 2015;66(16):20-5. https://doi.org/10.1016/j.jacc.2015.06.316

Djousse L, Khawaja O, Bartz M, Biggs M, Ix J, Zieman S, et al. Plasma fatty acid-binding protein 4, nonesterified fatty acids, and incident diabetes in older adults. Diabetes Care. 2012;35(8):1701-7. https://doi.org/10.2337/dc11-1690 PMid:22584136

Xu A, Wang Y, Xu J, Stejskal D, Tam S, Zhang J, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006;52:405-13. https://doi.org/10.1373/clinchem.2005.062463 PMid:16423904

Annette W, Aimin X, Pak C, Nelson M, Yu Wang, Carol H, et al. Serum adipocyte fatty acid-binding protein as a new biomarker predicting the development of type 2 diabetes: A 10-year prospective study in a Chinese cohort. Diabetes Care. 2007;30(10):2667-72. https://doi.org/10.2337/dc07-0413 PMid:17620449

Jeffrey B, Kazuhisa M, Makowski L, Babaev V, Fazio S, Linton M, et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004;110(11):1492- 98. https://doi.org/10.1161/01.cir.0000141735.13202.b6 PMid:15353487

Alssema M, Feskens E, Bakker S, Gansevoort R, Boer J, Heine R, et al. Finnish questionnaire reasonably good predictor of the incidence of diabetes in the Netherlands. Ned Tijdschr Geneeskd. 2008;152(44):2418-24. PMid:19055143

The Score Calculator; 2019. Available from: https://www. medsoftpro.ru/kalkulyatory/kalkulyator-score.html. [Last accessed on 2020 Jan 13].

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano Al, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European association for cardiovascular prevention and rehabilitation (EACPR). Eur J Prev Cardiol. 2016;23(11):1-96. https://doi.org/10.1007/s12529-016-9583-6 PMid:27353126

Abduelkarem A, Sharif S, Hammrouni A, Aldouibi S, Albraiki W, Shareif H. Risk calculation of developing type 2 diabetes Libyan adults. Pract Diabetes Int. 2009;26:148-51. https://doi. org/10.1002/pdi.1359

Mohieldein A, Mohieldein H, Alzohairy M, Hasan M. Risk estimation of Type 2 diabetes and dietary habits among adult Saudi non-diabetics in central Saudi Arabia. Glob J Health Sci. 2009;3:123-33. https://doi.org/10.5539/gjhs.v3n2p123

Naranjo A, Rodríguez А, Llera R. Diabetes risk in a Cuban primary care setting in persons with no known glucose abnormalities. MEDICC Rev. 2013;15(2):16-9. https://doi. org/10.37757/mr2013v15.n2.4 PMid:23686250

Sheryazdanova D, Ye L, Turmukhambetova A, Turgunova L. Assessment of the ten-year risk of developing T2DM in the Karaganda region: Population cross-sectional study. Med Ecol. 2016;2:64-8.

Daousi C, Casson I, Gill G, MacFarlane I, Wilding J, Pinkney J. Prevalence of obesity in type 2 diabetes in secondary care: Association with cardiovascular risk factors. Postgrad Med J. 2006;82(966):280-4. https://doi.org/10.1136/pmj.2005.039032 PMid:16597817

Chow W, Tso A, Xu A, Yuen M, Fong C, Lam T, et al. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: A 12-year prospective study. J Am Heart Assoc. 2013;2(1):e004176. https://doi.org/10.1161/jaha.112.004176 PMid:23525430

Ota H, Furuhashi M, Ishimura S, Koyama M, Okazaki Y, Mita T, et al. Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens. 2012;25(10):1124-30. https://doi. org/10.1038/ajh.2012.88 PMid:22717543

Djousséa L, Gazianoa J. Plasma levels of FABP4, but not FABP3, are associated with increased risk of diabetes. Lipids. 2012;47(8):757-62. https://doi.org/10.1007/ s11745-012-3689-7 PMid:22706792

Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: Implications for future risk assessment: Results from a large cohort study in Southern Germany. Circulation. 2004;109(11):1349-53. https://doi.org/10.1161/01.cir.0000120707.98922.e3 PMid:15023871

Eynatten M, Breitling L, Roos M, Baumann M, Rothenbacher D, Brenner H, et al. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: A 10-year prospective study. Arterioscler Thromb Vasc Biol. 2012;32(9):2327-35. https://doi. org/10.1161/atvbaha.112.248609 PMid:22679309